Company: ARTL
Filing Date: 2025-07-18
Form Type: 424B5
Source: 0001640334-25-001239
Chunk: 20

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-07-18
Form: 424B5
Chunk 20
---
 share to new investors to $11.67 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $14.67 per share shown in the table above, assuming all of our common stock in the aggregate amount of $6.50 million is sold at that price, would decrease our as adjusted net tangible book value per share after the offering to $4.73 per share and would decrease the dilution in net tangible book value per share to new investors to $9.949 per share, after deducting commissions and estimated aggregate offering expenses payable by us.

| S-16 |

The foregoing table assumes for illustrative purposes that an aggregate of 414,805 shares of our common stock are sold at a price of $15.67 per share, the last reported sale price of our common stock on the Nasdaq Capital Market on July 17, 2025, for aggregate gross proceeds of $6.50 million. The shares sold in this offering, if any, will be sold from time to time at various prices. The foregoing table also excludes the following as of that date:

| · | 128,976 shares of our common stock issuable upon the exercise of options or restricted stock awards granted under our 2018 Equity Incentive Plan (the “2018 Plan”), with a weighted-average exercise price of $11.02 per share; |
| · | 23,315 shares of our common stock issuable upon the exercise of warrants, with a weighted-average exercise price of $67.50 per share issued prior to June 2025;                                                                 |
| · | 123,255 shares of common stock issuable upon the voluntary conversion of convertible notes issued in our May 2025 private placement;                                                                                            |
| · | 246,511 shares of common stock issuable upon the automatic conversion of convertible notes issued in our May 2025 private placement to warrants to purchase common stock, with an exercise price of $1.04 per share;            |
| · | 136,843 shares of our common stock issued in our June 2025 private placement;                                                                                                                                                   |
| · | 93,180 shares of our common stock issuable upon the exercise of pre-funded warrants issued in our June 2025 private placement, with an exercise price of $0.001 per share;                                                      |
| · | 460,046 shares of our common stock iss